OncLive TV

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Cara A. Mathews, MD, discusses the updated findings from cohort D2 of the phase 1/2 RAINFOL-01 trial (NCT05579366) in advanced ovarian cancer.

Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease.

Raj Singh, MD, highlighted the importance of multidisciplinary collaboration in brain cancer management in observance of World Brain Tumor Day.

Heather Leeper, MD, discussed ideal survivorship care for geriatric patients with brain cancer.

Matthew Galsky, MD, discusses the emergence of ICIs the neoadjuvant setting of bladder cancer.

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

Matthew Galsky, MD, discusses the standing of immune checkpoint inhibitors in bladder cancer.

Matthew Galsky, MD, disusses how the treatment paradigm of bladder cancer has shifted over time.

Gerald Soff, MD, discusses data from the phase 3 RECITE trial showing that romiplostim reduces chemotherapy dose modifications in patients with GI cancer.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.

Tycel Phillips, MD, discusses the FDA approval of sonrotoclax in mantle cell lymphoma and where the agent can be best applied in the treatment paradigm.

Linda R. Mileshkin, MBBS, FRACP, Mbioeth, highlights efficacy data with puxitatug samrotecan in patients with ovarian and endometrial cancers.

Tony Mok, BMSc, MD, FRCPC, FHKCP, FHKAM, FRCP, notes the implications of 7-year data from the CROWN study of frontline lorlatinib in ALK-positive NSCLC.

Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.

Joyce Nuqui Barlin, MD, shares the rationale for studying gotistobart plus pembrolizumab in patients with pretreated platinum-resistant ovarian cancer.

Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.

Lucy Gilbert, MD, discusses overall survival data with relacorilant plus nab-paclitaxel based on prior taxane use from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Coral Olazagasti, MD, discusses the significance of providing resources to oncology physicians who are looking to strengthen their overall wellness.

Kelly Elizabeth McCann, MD, PhD, discusses the need for breast cancer research that encompasses drugs with different payloads.

Kelly Elizabeth McCann, MD, PhD, discusses the TROP2-directed ADCs that are clinically available for metastatic TNBC management.

Kelly Elizabeth McCann, MD, PhD, discusses considerations for the sequential use of ADCs with similar payloads in HER2-positive metastatic breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the role of post-neoadjuvant T-DXd in HER2-positive breast cancer.

Marwan G. Fakih, MD, discusses the synergy between liquid and tissue biopsies and the need for a data-driven approach to repeat ctDNA testing in CRC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Marwan G. Fakih, MD, discusses the pitfalls of using liquid TMB for immunotherapy selection and the need for tissue-liquid biopsy concordance in CRC.

Ginger J. Gardner, MD, FACOG, discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts.

Kelly Elizabeth McCann, MD, PhD, discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer.